Humira, approved in Europe for children and adolescents from four years of age with severe chronic plaque psoriasis
The European Commission ( EC ) has granted marketing authorization for Humira ( Adalimumab ) for the treatment of severe chronic plaque psoriasis in children and adolescents from four years of age who ...
read article